<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03634371</url>
  </required_header>
  <id_info>
    <org_study_id>Versión 3- BIO 096</org_study_id>
    <nct_id>NCT03634371</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Levothyroxine Sodium Tablets 150 mcg</brief_title>
  <official_title>Bioequivalence Study of Levothyroxine Sodium Tablets 150 mcg</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tecnoquimicas</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tecnoquimicas</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to establish the bioequivalence of two levothyroxine
      formulations through the estimation of T4 levels in serum samples after baseline correction,
      according to Food and Drugs Administration (FDA), World Health Organization (WHO) and
      Colombian National Vigilance Institute for Drugs and Food (INVIMA) guidelines.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Levothyroxine (T4) is used to treat patients with hypothyroidism and may often result in
      lifelong therapy. Its physiologically active metabolite is tri-iodothyronine (T3).
      Levothyroxine is also endogenously produced in the body. Since small changes in levothyroxine
      administration (e.g. change in brand or formulation) can cause significant changes in serum
      thyroid stimulating hormone (TSH) concentrations, precise and accurate TSH control is
      critical to avoid potential adverse iatrogenic effects. Tecnoquimicas modified its
      Levothyroxine tablets formulation in order to comply with new pharmacopeical specifications.
      It will then evaluate the impact on drug product performance based on pharmacokinetic (PK)
      measures of total serum T4 and total serum T3 of the new formulation of levothyroxine (Test
      formulation) relative to the reference formulation from Merck (Reference formulation)

      This will be a single-center, open-label, two-period, two-treatment, two-sequence,
      randomized, single-dose, crossover study. 80 healthy adults will be randomized to receive a
      single dose (4 x 150 mcg tablets = 600 mcg) of the test formulation of levothyroxine and
      reference formulation of levothyroxine separately in each treatment period. There will be two
      treatment sequences (AB, BA) and a 42 day washout between the two treatment periods.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 10, 2018</start_date>
  <completion_date type="Anticipated">October 6, 2018</completion_date>
  <primary_completion_date type="Anticipated">October 6, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>(AUC) Area Under the Curve 0-48 for T4</measure>
    <time_frame>From 0 to 48 hours</time_frame>
    <description>-0.5, -0.25, 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 and 48 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax for T4</measure>
    <time_frame>From 0 to 48 hours</time_frame>
    <description>-0.5, -0.25, 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 and 48 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC 0-48 for T3</measure>
    <time_frame>From 0 to 48 hours</time_frame>
    <description>-0.5, -0.25, 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 and 48 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax for T3</measure>
    <time_frame>From 0 to 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>From 0 to 48 hours</time_frame>
    <description>-0.5, -0.25, 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 and 48 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kel</measure>
    <time_frame>From 0 to 48 hours</time_frame>
    <description>-0.5, -0.25, 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 and 48 hours</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Test Formulation of Levothyroxine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levothyroxine sodium tablets 150 mcg Single dose of 600 mcg administered in dosing period 1 or 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference formulation of Levothyroxine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eutirox 150 mcg Single dose of 600 mcg administered in dosing period 1 or 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug Levothyroxine 150 mcg</intervention_name>
    <description>Administration of a 600 mcg levothyroxine dose</description>
    <arm_group_label>Test Formulation of Levothyroxine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug Eutirox 150 mcg</intervention_name>
    <description>Administration of a 600 mcg levothyroxine dose</description>
    <arm_group_label>Reference formulation of Levothyroxine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and Women from 18 to 50 years old

          -  Diagnosed as healthy after a clinical examination

          -  BMI from 18 to 30 kg/m2

          -  Not smoking for at least 3 months

          -  To sign the informed consent

          -  Not having participated in a similar study for at least 4 months

        Exclusion Criteria:

          -  Renal, cardiac immunological, dermatological, endocrine, gastrointestinal,
             neurological or psychiatric condition

          -  Hematologic disorders, specially anemia and polycythemia

          -  Permanent or temporal pharmacological therapy, prescribed or not

          -  Smoking for the last 3 months

          -  Alcohol drinker more than once a week

          -  Drug abuse

          -  Drug hypersensitivity

          -  Angioedema or anaphylaxis history

          -  Pregnancy or breast-feeding

          -  HIV o Hepatitis B diagnosed

          -  Blood donor in the past 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Universidad de la Sabana</name>
      <address>
        <city>Chía</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 12, 2018</study_first_submitted>
  <study_first_submitted_qc>August 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2018</study_first_posted>
  <last_update_submitted>August 14, 2018</last_update_submitted>
  <last_update_submitted_qc>August 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tecnoquimicas</investigator_affiliation>
    <investigator_full_name>Mauricio Vargas</investigator_full_name>
    <investigator_title>Biopharmaceutical Studies Director</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

